Newer Targeted Approaches in Medullary Thyroid Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.

      Recent Videos
      Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
      2025 ASCO Annual Meeting: The Show and After Show
      Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
      Taste Change Data May Inform Radiotherapy Strategy in Head and Neck Cancer
      Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
      Data Show Substantial Taste Changes in Head and Neck Cancer Following RT
      Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
      Measuring Objective Taste Changes in Head and Neck Cancer Population After RT
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
      Assessing the Future With “Promising” Antibody Drug Conjugates in Breast Cancer
      Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
      Mitigating ILD Following T-DXd in HR+, HER2-Low Metastatic Breast Cancer
      Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
      Ensuring Quality of Life in Chronic Myeloid Leukemia Populations
      Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
      Formulating Questions for Clinicians to Understand a CML Diagnosis
      Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
      Defining Goals of Therapy in Chronic Myeloid Leukemia
      Related Content
      No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

      No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

      Kristi Rosa
      June 3rd 2025
      Article

      Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

      Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

      Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

      Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
      May 26th 2025
      Podcast

      Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

      Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer

      Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer

      Bridget Hoyt
      June 3rd 2025
      Article

      Data suggest that anti-inflammatory diets and regular physical activity are associated with improved overall survival in patients with stage III resected colon cancer.

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

      Neil M. Iyengar, MD;Paolo Tarantino, MD
      June 17th 2024
      Podcast

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

      Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma

      Roman Fabbricatore
      June 1st 2025
      Article

      Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

      Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer

      Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer

      Ariana Pelosci
      June 1st 2025
      Article

      Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.